Aspen Neuroscience announced the closing of a $115 million Series C financing round, which will be used to fuel the continued development of ANPD001, the company’s lead autologous cell therapy candidate for moderate to advanced Parkinson’s disease.
In addition to supporting ongoing clinical trials of ANPD001, the funds will enable Aspen to scale manufacturing capabilities to meet clinical and future commercial demand, as well as advance its pipeline of autologous iPSC-derived therapies for additional neurological indications.
The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from existing investors including Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, and LifeForce Capital. Gilead’s Kite was among the new investors. The latest funding brings Aspen’s total capital raised to date to over $340 million, including an $8 million grant from California Institute for Regenerative Medicine.
According to Aspen, ANPD001, currently in phase 1/2a trials, is the most advanced autologous investigational cell therapy in the U.S. for treating Parkinson’s disease. Aspen’s personalized approach means that patients do not require immunosuppressive (IS) drugs to dampen the body’s immune response against foreign cells, which can help avoid IS‑associated adverse events, eliminate IS drug‑monitoring requirements, and enable dosing for those with contraindications to IS therapies.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!